Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Acinetobacter Baumannii Infection Clinical Trial

Official title:

Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02886637
• Other study ID #: 20160826
• Status: Completed
• Phase: N/A
• First received: August 27, 2016
• Last updated: August 31, 2016
• Start date: July 2015
• Est. completion date: March 2016

Study information

• Verified date: August 2016
• Source: Southeast University, China
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.

Description:

This is a single-center, observational study. Patients with Acinetobacter baumannii infection in the intensive care unit of Zhongda Hospital were enrolled. We recorded the data of age, ICU admission diagnosis, underlying diseases, APACHE II score and infection site. Body temperature, heart rate, white blood cell counts, procalcitonin, C-reactive protein, SOFA score and the level of CD4+, CD8+, Th1, Th2 and HLA-DR in the blood measured by flow cytometry on the D1, D3 and D7 were also recorded.We can get the results of the change of immune function of critical ill patients after Acinetobacter baumannii infection. After compare the patients who die of survive at 28 day after infection, we can get the results of the relationship between the immune function and the outcome. We also can calculate the effect immune function on prognositic mortality in patients with Acinetobacter baumannii infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients admitted to ICU

• Infection with Acinetobacter baumannii

• Agree to participate the study

Exclusion Criteria:

• Age less than 16 years old or older than 80 years old

• pregnancy

• immunosuppression patients which include

1. therapy 0.5mg/kg/day of prednisoneover(equivalent dose of other glucocorticoids) for at least 1 month within recent 3 month

2. Cancer chemotherapy within recent 3 month

3. Receive immunosuppression treatment because of solid organ transplant or Autoimmune diseases

4. allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation.

5. HIV infection

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acinetobacter Baumannii Infection
• Communicable Diseases
• Infection

Intervention

Other:
• None intervention

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Southeast University, China

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	28 day mortality		28 day	No